tofacitinib and Epidermolysis-Bullosa-Dystrophica

tofacitinib has been researched along with Epidermolysis-Bullosa-Dystrophica* in 1 studies

Other Studies

1 other study(ies) available for tofacitinib and Epidermolysis-Bullosa-Dystrophica

ArticleYear
Successful use of tofacitinib in epidermolysis bullosa pruriginosa.
    Clinical and experimental dermatology, 2022, Volume: 47, Issue:3

    This case report describes 26-year-old woman who had multiple clusters of pale-pink lichenoid papules since childhood and the accompanying itching was intense. Skin biopsy revealed obvious fissures had formed under the epidermis. The patient was diagnosed with epidermolysis bullosa pruriginosa and was successfully treated with tofacitinib.

    Topics: Adult; Dermatologic Agents; Epidermolysis Bullosa Dystrophica; Female; Humans; Janus Kinase Inhibitors; Piperidines; Pruritus; Pyrimidines

2022